Reuters logo
BRIEF-Poxel says ‍imeglimin Phase 2b trial achieved statistically significant results
September 14, 2017 / 6:09 AM / 13 days ago

BRIEF-Poxel says ‍imeglimin Phase 2b trial achieved statistically significant results

Sept 14 (Reuters) - POXEL SA

* ‍IMEGLIMIN PHASE 2B TRIAL IN 299 JAPANESE PATIENTS ACHIEVED STATISTICALLY SIGNIFICANT RESULTS FOR ITS PRIMARY AND SECONDARY ENDPOINTS​

* ‍POXEL RECENTLY COMPLETED END OF PHASE 2 MEETING FOR IMEGLIMIN WITH JAPANESE REGULATORS AND PLANS TO INITIATE PHASE 3 PROGRAM IN Q4 OF 2017​

* ‍OVERALL, STUDY SHOWED THAT IMEGLIMIN WAS SAFE AND WELL TOLERATED​ Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below